Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week

Chart, Trading, Forex, Analysis, Tablet, Pc

Image Source: Pixabay

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 3.4%, on average, last week and below is how each constituent stock performed, in descending order, and YTD, plus any recent news, commentary, and/or analysis on each company:

  1. Mind Medicine (MNMD): UP 55.7% last week; UP 165.0% YTD
  2. Atai Life Sciences (ATAI): DOWN 1.4% last week; UP 48.9% YTD
  3. GH Research (GHRS): DOWN 4.6% last week; UP 39.8% YTD
  4. Compass Pathways (CMPS): DOWN 5.2% last week; UP 24.3% YTD
  5. Incannex Healthcare (IXHL): DOWN 23.9% last week; DOWN 10.1% YTD
    • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
    • Latest News, Commentary and/or Analysis: None


The munKNEE Psychedelic compound-Based Drug Stocks Index went UP 3.4% last week and is now UP 44.1% YTD.

More By This Author:

Our 7 Largest Cannabis MSO Stocks Dropped 7.1% Last Week
Cannabis Company Green Thumb Has Bounced Back From A Rocky Q4
Q4 Results Of Cannabis Company Verano Holdings Were Down Across The Board

Disclosure: None

This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.